mirtazapine has been researched along with Anorexia in 10 studies
Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was conducted to assess the efficacy and tolerability of mirtazapine in cancer-associated anorexia and cachexia." | 9.41 | Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial. ( Abdel-Aal, HH; Alsirafy, SA; Elsherief, WA; Farag, DE; Hunter, CN; Riad, NM, 2021) |
| "We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 9.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
| "This study was conducted to assess the efficacy and tolerability of mirtazapine in cancer-associated anorexia and cachexia." | 5.41 | Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial. ( Abdel-Aal, HH; Alsirafy, SA; Elsherief, WA; Farag, DE; Hunter, CN; Riad, NM, 2021) |
| "Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea." | 5.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
| "Cats with chronic kidney disease (CKD) often experience inappetence and vomiting and might benefit from the administration of mirtazapine, a medication with appetite stimulant and anti-nausea properties." | 5.17 | Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. ( Lunn, KF; Quimby, JM, 2013) |
| "We performed an open-label single-institution phase II trial of mirtazapine (15-30 mg by mouth [po] every day [qd]), a tetracyclic antidepressant that may lead to weight gain, for 8 weeks in nondepressed patients with cancer-related cachexia/anorexia (CRCA)." | 5.14 | Phase II trial of mirtazapine for cancer-related cachexia and anorexia. ( Burman, D; Riechelmann, RP; Rodin, G; Tannock, IF; Zimmermann, C, 2010) |
| "Depression is quite common among cancer patients." | 2.73 | An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients. ( Elbi, H; Ersoy, MA; Noyan, AM, 2008) |
| "Anorexia is the common symptom of malnutrition in cancer patients." | 2.72 | Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment. ( Hariyanto, TI; Kurniawan, A, 2021) |
| " Adverse events were commonly seen in the oncology population." | 1.72 | Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients. ( Burger, A; Eladghm, N; Gamaleldin, A; Marie Gavioli, E; Vider, E, 2022) |
| "Mirtazapine is a new antidepressant called noradrenergic and specific serotonergic antidepressant(NaSSA)and blocks 5-HT3 receptors to improve nausea." | 1.38 | [Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy]. ( Imai, E; Ito, T; Nishimura, D; Shibahara, H; Uematsu, N, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Marie Gavioli, E | 1 |
| Burger, A | 1 |
| Gamaleldin, A | 1 |
| Eladghm, N | 1 |
| Vider, E | 1 |
| Wyatt, D | 1 |
| Santoro, D | 1 |
| Deabold, K | 1 |
| Gruntmeir, J | 1 |
| Childress, A | 1 |
| Craft, WF | 1 |
| Walden, HDS | 1 |
| Wellehan, JFX | 1 |
| Mendoza, KA | 1 |
| Stockinger, DE | 1 |
| Cukrov, MJ | 1 |
| Roberts, JA | 1 |
| Hwa, GGC | 1 |
| Hariyanto, TI | 1 |
| Kurniawan, A | 1 |
| Hunter, CN | 1 |
| Abdel-Aal, HH | 1 |
| Elsherief, WA | 1 |
| Farag, DE | 1 |
| Riad, NM | 1 |
| Alsirafy, SA | 1 |
| Quimby, JM | 1 |
| Lunn, KF | 1 |
| Riechelmann, RP | 1 |
| Burman, D | 1 |
| Tannock, IF | 1 |
| Rodin, G | 1 |
| Zimmermann, C | 1 |
| Shibahara, H | 1 |
| Ito, T | 1 |
| Uematsu, N | 1 |
| Imai, E | 1 |
| Nishimura, D | 1 |
| Fountoulakis, KN | 1 |
| Iacovides, A | 1 |
| Siamouli, M | 1 |
| Koumaris, V | 1 |
| Kaprinis, GS | 1 |
| Ersoy, MA | 1 |
| Noyan, AM | 1 |
| Elbi, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care.[NCT03283488] | Phase 2 | 52 participants (Actual) | Interventional | 2019-03-26 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for mirtazapine and Anorexia
| Article | Year |
|---|---|
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment.
Topics: Anorexia; Appetite; Clinical Trials, Phase III as Topic; Eicosapentaenoic Acid; Growth Differentiati | 2021 |
4 trials available for mirtazapine and Anorexia
| Article | Year |
|---|---|
Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.
Topics: Anorexia; Cachexia; Double-Blind Method; Hand Strength; Humans; Mirtazapine; Neoplasms | 2021 |
Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial.
Topics: Animals; Anorexia; Antiemetics; Appetite Stimulants; Cat Diseases; Cats; Cross-Over Studies; Female; | 2013 |
Phase II trial of mirtazapine for cancer-related cachexia and anorexia.
Topics: Aged; Aged, 80 and over; Anorexia; Antidepressive Agents, Tricyclic; Appetite; Body Weight; Cachexia | 2010 |
An open-label long-term naturalistic study of mirtazapine treatment for depression in cancer patients.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antidepressive Agents, Tricyclic; Depressive Disorder; | 2008 |
5 other studies available for mirtazapine and Anorexia
| Article | Year |
|---|---|
Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients.
Topics: Adult; Aged; Anorexia; Appetite; Appetite Stimulants; Cachexia; Hallucinations; Humans; Long QT Synd | 2022 |
Subcutaneous nodules and dermatitis associated with non-
Topics: Animals; Anorexia; Antidepressive Agents; Cat Diseases; Cats; Dermatitis; Dirofilaria; Dirofilariasi | 2020 |
Effects of transdermal mirtazapine on hyporexic rhesus and cynomolgus macaques (Macaca mulatta and Macaca fascicularis).
Topics: Administration, Cutaneous; Animals; Anorexia; Appetite Stimulants; Female; Macaca fascicularis; Maca | 2021 |
[Low-dose mirtazapine improved nausea and appetite loss during S-1 therapy].
Topics: Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Combinations; Histamine H1 Antago | 2012 |
Successful treatment of anorexia with a combination of high-dose olanzapine, fluoxetine and mirtazapine.
Topics: Adult; Anorexia; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsy | 2006 |